FOXA1 and adenocarcinoma: We also conducted further pathologic review of the 24 samples with class 2 mutations (Supplementary Tables S3 and S4) and determined that 16 were adenocarcinomas morphologically (66.6%), whereas eight (33.3%) were nonadenocarcinomas (five small-cell prostate cancers and three NEPCs; ref. 20); 14 of the 16 FOXA1 class 2–mutant adenocarcinomas were from metastatic sites.